HHS Guidance Aims To Curb Overreporting Of Clinical-Trial Adverse Events
This article was originally published in The Gray Sheet
Executive Summary
A final HHS 1guidance explains that only a small subset of adverse events occurring in HHS-funded clinical research need be reported